BACKGROUND: Hypertension is the most prevalent comorbidity in individuals with chronic kidney disease. However, whether the association of the kidney disease measures, estimated glomerular filtration rate (eGFR) and albuminuria, with mortality or end-stage renal disease (ESRD) differs by hypertensive status is unknown. METHODS: We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and ESRD associated with eGFR and albuminuria in individuals with and without hypertension. FINDINGS: We analysed data for 45 cohorts (25 general population, seven high-risk, and 13 chronic kidney disease) with 1,127,656 participants, 364,344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts. All-cause mortality risk was 1·1-1·2 times higher in individuals with hypertension than in those without hypertension at preserved eGFR. A steeper relative risk gradient in individuals without hypertension than in those with hypertension at eGFR range 45-75 mL/min per 1·73 m(2) led to much the same mortality risk at lower eGFR. With a reference eGFR of 95 mL/min per 1·73 m(2) in each group to explicitly assess interaction, adjusted HR for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) was 1·77 (95% CI 1·57-1·99) in individuals without hypertension versus 1·24 (1·11-1·39) in those with hypertension (p for overall interaction=0·0003). Similarly, for albumin-creatinine ratio of 300 mg/g (vs 5 mg/g), HR was 2·30 (1·98-2·68) in individuals without hypertension versus 2·08 (1·84-2·35) in those with hypertension (p for overall interaction=0·019). We recorded much the same results for cardiovascular mortality. The associations of eGFR and albuminuria with ESRD, however, did not differ by hypertensive status. Results for chronic kidney disease cohorts were similar to those for general and high-risk population cohorts. INTERPRETATION: Chronic kidney disease should be regarded as at least an equally relevant risk factor for mortality and ESRD in individuals without hypertension as it is in those with hypertension. FUNDING: US National Kidney Foundation.
BACKGROUND: Hypertension is the most prevalent comorbidity in individuals with chronic kidney disease. However, whether the association of the kidney disease measures, estimated glomerular filtration rate (eGFR) and albuminuria, with mortality or end-stage renal disease (ESRD) differs by hypertensive status is unknown. METHODS: We did a meta-analysis of studies selected according to Chronic Kidney Disease Prognosis Consortium criteria. Data transfer and analyses were done between March, 2011, and June, 2012. We used Cox proportional hazards models to estimate the hazard ratios (HR) of mortality and ESRD associated with eGFR and albuminuria in individuals with and without hypertension. FINDINGS: We analysed data for 45 cohorts (25 general population, seven high-risk, and 13 chronic kidney disease) with 1,127,656 participants, 364,344 of whom had hypertension. Low eGFR and high albuminuria were associated with mortality irrespective of hypertensive status in the general population and high-risk cohorts. All-cause mortality risk was 1·1-1·2 times higher in individuals with hypertension than in those without hypertension at preserved eGFR. A steeper relative risk gradient in individuals without hypertension than in those with hypertension at eGFR range 45-75 mL/min per 1·73 m(2) led to much the same mortality risk at lower eGFR. With a reference eGFR of 95 mL/min per 1·73 m(2) in each group to explicitly assess interaction, adjusted HR for all-cause mortality at eGFR 45 mL/min per 1·73 m(2) was 1·77 (95% CI 1·57-1·99) in individuals without hypertension versus 1·24 (1·11-1·39) in those with hypertension (p for overall interaction=0·0003). Similarly, for albumin-creatinine ratio of 300 mg/g (vs 5 mg/g), HR was 2·30 (1·98-2·68) in individuals without hypertension versus 2·08 (1·84-2·35) in those with hypertension (p for overall interaction=0·019). We recorded much the same results for cardiovascular mortality. The associations of eGFR and albuminuria with ESRD, however, did not differ by hypertensive status. Results for chronic kidney disease cohorts were similar to those for general and high-risk population cohorts. INTERPRETATION: Chronic kidney disease should be regarded as at least an equally relevant risk factor for mortality and ESRD in individuals without hypertension as it is in those with hypertension. FUNDING: US National Kidney Foundation.
Authors: Csaba P Kovesdy; Bhairvi K Trivedi; Kamyar Kalantar-Zadeh; John E Anderson Journal: Nephrol Dial Transplant Date: 2006-01-18 Impact factor: 5.992
Authors: H Borsboom; L Smans; M J M Cramer; J C Kelder; M P Kooistra; P F Vos; B C van Jaarsveld Journal: Neth J Med Date: 2005-11 Impact factor: 1.422
Authors: Catherine M Clase; Peggy Gao; Sheldon W Tobe; Matthew J McQueen; Anja Grosshennig; Koon K Teo; Salim Yusuf; Johannes F E Mann Journal: Ann Intern Med Date: 2011-03-01 Impact factor: 25.391
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Steven J Chadban; Esther M Briganti; Peter G Kerr; David W Dunstan; Timothy A Welborn; Paul Z Zimmet; Robert C Atkins Journal: J Am Soc Nephrol Date: 2003-07 Impact factor: 10.121
Authors: Gülmisal Güder; Stefan Frantz; Johann Bauersachs; Bruno Allolio; Christoph Wanner; Michael T Koller; Georg Ertl; Christiane E Angermann; Stefan Störk Journal: Circ Heart Fail Date: 2009-09-24 Impact factor: 8.790
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Marije van der Velde; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Jackson Wright; Larry Appel; Tom Greene; Adeera Levin; Ognjenka Djurdjev; David C Wheeler; Martin J Landray; John N Townend; Jonathan Emberson; Laura E Clark; Alison Macleod; Angharad Marks; Tariq Ali; Nicholas Fluck; Gordon Prescott; David H Smith; Jessica R Weinstein; Eric S Johnson; Micah L Thorp; Jack F Wetzels; P J Blankestijn; A D van Zuilen; Vandana Menon; Mark Sarnak; Gerald Beck; Florian Kronenberg; Barbara Kollerits; Marc Froissart; Benedicte Stengel; Marie Metzger; Giuseppe Remuzzi; Piero Ruggenenti; Annalisa Perna; H J Lambers Heerspink; Barry Brenner; Dick de Zeeuw; Peter Rossing; Hans-Henrik Parving; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Todd H Driver; Ronit Katz; Joachim H Ix; Jared W Magnani; Carmen A Peralta; Chirag R Parikh; Linda Fried; Anne B Newman; Stephen B Kritchevsky; Mark J Sarnak; Michael G Shlipak Journal: Am J Kidney Dis Date: 2014-03-18 Impact factor: 8.860
Authors: Ana C Ricardo; Cheryl A Anderson; Wei Yang; Xiaoming Zhang; Michael J Fischer; Laura M Dember; Jeffrey C Fink; Anne Frydrych; Nancy G Jensvold; Eva Lustigova; Lisa C Nessel; Anna C Porter; Mahboob Rahman; Julie A Wright Nunes; Martha L Daviglus; James P Lash Journal: Am J Kidney Dis Date: 2014-11-20 Impact factor: 8.860
Authors: Matthew T James; Morgan E Grams; Mark Woodward; C Raina Elley; Jamie A Green; David C Wheeler; Paul de Jong; Ron T Gansevoort; Andrew S Levey; David G Warnock; Mark J Sarnak Journal: Am J Kidney Dis Date: 2015-05-11 Impact factor: 8.860